Ardelyx (ARDX) Downgraded by BidaskClub
Ardelyx (NASDAQ:ARDX) was downgraded by equities researchers at BidaskClub from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday.
Other equities analysts have also issued reports about the stock. Cantor Fitzgerald set a $12.00 target price on shares of Ardelyx and gave the stock a “buy” rating in a research report on Monday. Zacks Investment Research lowered shares of Ardelyx from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. Wedbush reaffirmed an “outperform” rating and set a $12.00 target price (down from $13.00) on shares of Ardelyx in a research report on Tuesday, November 28th. Ladenburg Thalmann Financial Services reduced their target price on shares of Ardelyx from $19.00 to $16.00 and set a “buy” rating on the stock in a research report on Wednesday, November 22nd. Finally, Citigroup raised their target price on shares of Ardelyx from $16.00 to $17.00 and gave the stock a “buy” rating in a research report on Wednesday, November 29th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $12.93.
Shares of Ardelyx (NASDAQ ARDX) opened at $5.80 on Wednesday. Ardelyx has a 1 year low of $4.05 and a 1 year high of $15.40. The firm has a market cap of $275.18, a PE ratio of -2.60 and a beta of 0.44.
COPYRIGHT VIOLATION WARNING: “Ardelyx (ARDX) Downgraded by BidaskClub” was originally reported by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at https://www.watchlistnews.com/ardelyx-ardx-downgraded-by-bidaskclub/1864533.html.
Ardelyx Company Profile
Ardelyx, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. It operates through the research, development and commercialization of biopharmaceutical products segment. The Company’s products line includes cardiorenal portfolio and gastrointestinal portfolio.
Receive News & Ratings for Ardelyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardelyx and related companies with MarketBeat.com's FREE daily email newsletter.